健康元：公司玛帕西沙韦干混悬剂（儿童剂型，适配2-12岁）研发进展顺利

Core Viewpoint - The company is making significant progress in the development of its pediatric formulation of Maropitant citrate suspension, which is designed for children aged 2-12 years, aiming to address the treatment needs for influenza in this demographic [2] Group 1: Product Development - The pediatric formulation has received CDE exemption to skip Phase II clinical trials and directly enter Phase III [2] - The first subject has been enrolled as of November 2025, and the company is currently in a critical phase of enrollment and data accumulation for Phase III [2] - The development cycle has been shortened due to the established target mechanism and clinical data from the adult formulation, Maropitant citrate capsules [2] Group 2: Market Strategy - The company is optimizing the production process and supply chain for the pediatric formulation [2] - There is an intention to accelerate the Phase III clinical progress to complete core data and submit a New Drug Application (NDA) as soon as possible [2] - The pediatric formulation is expected to synergize with the adult capsules, aiming for comprehensive coverage of the influenza treatment market across all age groups [2]